Objectives-This investigation was designed to monitor altitude acclimatisation in an elite cohort of distance runners and follow the subsequent recovery from infectious mononucleosis which developed in one of these athletes. Methods-Twenty six national standard distance runners performed treadmill tests 24 days before they travelled to an altitude camp (1500 to 2000 m). One of these athletes was diagnosed as suffering from infectious mononucleosis 14 days after return to sea level. A physician prescribed an individualised training programme which was designed to maximise recovery from the condition, which was monitored on days 16 and 147 after altitude training. Results and Conclusions-The data suggest that the athlete was in a state of over-reaching during the altitude sojourn. After return to sea level, the early stages of infectious mononucleosis resulted in a marked impairment in physiological response to endurance exercise, which improved over time. Longitudinal physiological monitoring in conjunction with a carefully prescribed training programme made recovery from this condition possible. (BrJ Sports Med 1997;31:153-154) 
Infection with the Epstein-Barr virus, a DNA virus of the herpes group, causes infectious mononucleosis, which results in a positive Paul-Bunnell test after ten days. The infection is a self limiting lymphoproliferative disease, limited mainly to the B lymphocytes and results in some immunosuppression in its active form.' This case study recorded the impact and subsequent recovery from infectious mononucleosis on the health status and endurance performance of an elite competitor. The subject gave signed consent for the publication of this case study.
Case report
The subject was an international standard 800/ 1500 m male runner with a body mass of 70. 8 kg. Arterialised The data summarised in table 1 identified that infectious mononucleosis was associated with changes in the kinetics of lactate production and removal and recovery of HR during exercise. These changes may be mediated by chronic stimulation of the sympathoadrenal system, which has been shown to cause accelerated glycogenolysis through activation of the rate limiting enzymes phosphorylase and phosphofructokinase.7
The additive stress of a reduction in the inspiratory Po, in conjunction with the extensive training loads employed by this subject at altitude may have precipitated a less favourable change in immune function. The precise aetiology of hypoxia mediated immunosupression is not known, but the immunomodulatory role of endogenous glucocorticoids and neuropeptides, which are increased at altitude, need to be considered.8 In a recent investigation,9 we demonstrated a significant decrease in resting plasma glutamine concentrations in elite distance runners who trained at 1640 m above sea level in comparison with pre-altitude values. This has been identified in overtrained athletes at sea level and may be a contributory factor leading to immunosupression and underperformance.'0 It has been suggested that oral glutamine supplementation (5 g L-glutamine per day) may counteract the immunosupression associated with endurance exercise." If these findings are confirmed, then it is probable that similar advice may serve to maintain normal immune function and thus optimise performance in elite athletes who train at altitude.
Summary
An individualised tapered training programme, in conjunction with continuous physiological and medical assessments, made it possible for this athlete to recover from infectious mononucleosis while maintaining a significant level of aerobic fitness. Ten months after diagnosis, the subject recorded a personal best time for 1500 m indoors. After and during an illness, longitudinal monitoring and consultation has serious implications for both the fitness and the health of the elite competitor. 
